New Standard of Care in Frontline Treatment of Mantle Cell Lymphoma
Introduction
A phase 3 trial conducted across 165 secondary or tertiary university, community or private hospitals and clinical centers in Europe was aimed at studying the superior efficacy of ibrutinib-containing chemoimmunotherapy versus the pre-trial standard approach with ASCT consolidation in the frontline treatment of MCL. The latest findings were presented at the 2022 ASH annual meeting, which showed better outcomes from ibrutinib-containing chemoimmunotherapy. The safety and efficacy of this approach could potentially lead to a new standard of care for young, medically fit patients with MCL who haven’t received previous treatment.
Methodology and Findings
Patients selected for this study were between 18 and 65 years of age, with previously untreated, histologically confirmed MCL that was Ann Arbor stage II to IV, suitable for treatment with ASCT, had a minimum of one measurable lesion on their body, and had an ECOG performance score of 2 or less. The trial enrolled 870 patients randomly assigned to three treatment groups: group A, group A+I, and group I. The primary endpoint of the study was failure-free survival (FFS), which was defined as either stable disease at the end of induction immunochemotherapy, progressive disease, or death from any cause on the trial — whichever occurred first.
At a median follow-up of 31 months (95% CI, 30.1-33.0), patients randomly assigned to receive chemoimmunotherapy plus ASCT (group A; n = 288) exhibited a 3-year failure-free survival (FFS) rate of 72% (95% CI, 67%-79%), while those who received ibrutinib plus chemoimmunotherapy and ASCT (group A+I; n = 292) exhibited an FFS rate of 88% (95% CI, 84%-92%; HR
Originally Post From https://www.oncnursingnews.com/view/ibrutinib-plus-chemoimmunotherapy-induction-improves-failure-free-survival-in-young-patients-with-mcl
Read more about this topic at
Tumor microenvironment influences survival of mantle cell …
Fibroblast Growth Factor-1 Inhibition Enhances FAS …
